New insider activity at Repligen ( (RGEN) ) has taken place on March 20, 2025.
Director Anthony Hunt has recently executed a significant transaction by selling 26,756 shares of Repligen stock, amounting to a total value of $4,080,663. This move highlights a notable shift in the director’s holdings within the company.
Recent Updates on RGEN stock
Repligen has recently made headlines with its strategic acquisition of 908 Devices’ bioprocessing assets for $70 million in cash, which is expected to expand its opportunities in upstream bioprocessing and high-growth modalities such as RNA and cell therapies. This acquisition has led to positive analyst sentiment, with RBC Capital highlighting the potential for growth in new bioprocessing opportunities. Additionally, Evercore ISI initiated coverage of Repligen, noting its potential to outperform market growth due to its differentiated products and higher clinical mix. However, Repligen has also announced a delay in filing its 2024 yearly report, citing the need for additional time to complete year-end reporting procedures. Despite this, the company does not anticipate any changes in its previously disclosed financial results.
More about Repligen
YTD Price Performance: 0.90%
Average Trading Volume: 628,095
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.09B
Questions or Comments about the article? Write to editor@tipranks.com